WeightWatchers braces for Oprah’s primetime GLP-1 special; Pfizer CEO Albert Bourla’s pay fell 35% to $21.6 million; Insurers meeting with federal officials about Change Healthcare outage.
FDA rules on Madrigal Pharmaceuticals’ NASH therapy; Wegovy’s label expansion to heart disease may spur Medicare to expand coverage; Vice President Kamala Harris visits abortion clinic.
AstraZeneca expands into rare endocrinology with $1B deal for Amolyt Pharma
Pfizer reports promising findings in late-stage blood cancer trial; Merck announces a deal with Pearl Bio that could top $1 billion; Allegra launches GPS for clean-air pathways at South by Southwest.
Rx Rundown: Bayer, Gilead Sciences, Akero Therapeutics and more
Looking at the year ahead, Haleon projected organic revenue growth between 4% to 6% as well as organic operating profit growth exceeding organic revenue growth.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix